{"id":7503,"date":"2019-03-11T00:00:00","date_gmt":"2019-03-10T23:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2019\/03\/11\/el-15-dels-pacients-de-cancer-pateix-algun-tipus-de-tumor-minoritari\/"},"modified":"2020-05-13T19:46:06","modified_gmt":"2020-05-13T17:46:06","slug":"el-15-dels-pacients-de-cancer-pateix-algun-tipus-de-tumor-minoritari","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2019\/03\/el-15-dels-pacients-de-cancer-pateix-algun-tipus-de-tumor-minoritari\/","title":{"rendered":"El 15% dels pacients de c\u00e0ncer pateix algun tipus de tumor minoritari"},"content":{"rendered":"<p>Aquest any la instituci\u00f3 dedica la seva campanya anual de recaptaci\u00f3 de fons a la investigaci\u00f3 en c\u00e0ncer. Bona part del que es recapti\u00a0anir\u00e0 destinat a la lluita contra els c\u00e0ncers rars o minoritaris, que tan sols a Catalunya representen quasi el 14% dels casos, afectant a unes 5.000 persones.<strong>\u00a0<\/strong>\n<\/p>\n<p>\u00a0<\/p>\n<p>El c\u00e0ncer colorectal, amb una incid\u00e8ncia del 17%, i el c\u00e0ncer de mama, amb un 12% s\u00f3n els tipus de c\u00e0ncer m\u00e9s freq\u00fcents a Espanya; un pa\u00eds on aquesta malaltia \u00e9s la primera causa de mortalitat en homes i la segona en dones.<\/p>\n<p>\u00a0<\/p>\n<p>Amb aquesta alt\u00edssima afectaci\u00f3, el cert \u00e9s que gran part dels fons dedicats a la investigaci\u00f3 en c\u00e0ncer es destinen a accelerar la lluita contra aquests tumors d\u2019alta incid\u00e8ncia. S\u00f3n unes noticies excel\u00b7lents si no fos perqu\u00e8, en aquest context, existeixen diferents tipus de c\u00e0ncers rars o minoritaris que en la carrera pel finan\u00e7ament en investigaci\u00f3 es veuen relegats a un segon pla.<\/p>\n<p>\u00a0<\/p>\n<p>\u201cLa lluita contra els c\u00e0ncers minoritaris \u00e9s dif\u00edcil. L\u2019any passat, nom\u00e9s a Catalunya es van diagnosticar 36.500 nous casos de c\u00e0ncer, dels quals 5.000 s\u00f3n considerats rars. Cada un afecta a menys de l\u20191% de la poblaci\u00f3. Per\u00f2 sumats un a un poden arribar a representar el 15% del total de tumors\u201d subratlla Gabriel Capell\u00e1, director de l\u2019IDIBELL.<\/p>\n<p>\u00a0<\/p>\n<p>\u201cQuan la freq\u00fc\u00e8ncia d\u2019afectaci\u00f3 \u00e9s minorit\u00e0ria existeix menys pressi\u00f3 social i cient\u00edfica per finan\u00e7ar la investigaci\u00f3. \u00c9s necessari seguir investigant per reduir el temps de diagn\u00f2stic i aconseguir cronificar i curar la malaltia en el major nombre de persones possible, incloses aquelles afectades per tumors de menor incid\u00e8ncia\u201d, conclou Capell\u00e1.<\/p>\n<p>\u00a0<\/p>\n<p>Al gener l\u2019IDIBELL va posar en marxa la campanya #josalvovides, en la que ciutadans, empreses i mitjans de comunicaci\u00f3 son cridats a col\u00b7laborar mitjan\u00e7ant aportacions econ\u00f2miques, assist\u00e8ncia als actes programats i difusi\u00f3 dels missatges i de les vies de col\u00b7laboraci\u00f3.<\/p>\n<p>\u00a0<\/p>\n<p><strong>Web de donacions, un espot d\u2019homenatge als donants an\u00f2nims i un Sopar Ben\u00e8fic contra el c\u00e0ncer<\/strong><\/p>\n<p>\u00a0<\/p>\n<p>La campanya #josalvovides #yosalvovidas es va posar en marxa el passat mes de gener i rendeix homenatge als donants an\u00f2nims, per agrair la col\u00b7laboraci\u00f3 de la ciutadania per reunir recursos i ajudar a ampliar les alternatives terap\u00e8utiques i la qualitat de vida dels malalts de c\u00e0ncer a trav\u00e9s de la investigaci\u00f3.<\/p>\n<p>\u00a0<\/p>\n<p>El missatge \u00e9s clar, explica el Dr. Ramon Salazar, coordinador del programa Oncobell: \u201cActualment ja som un centre de refer\u00e8ncia en el tractament de tumors minoritaris i cada dia avancem m\u00e9s cap a l\u2019aplicaci\u00f3 de ter\u00e0pies personalitzades. Quanta m\u00e9s inversi\u00f3, m\u00e9s de pressa avan\u00e7arem i m\u00e9s vides podrem salvar\u201d, explica.<\/p>\n<p>\u00a0<\/p>\n<p>L\u2019acte principal de campanya es concreta en una Gala ben\u00e8fica per a la investigaci\u00f3 del c\u00e0ncer. L\u2019esdeveniment que, entre altres personalitats, comptar\u00e0 amb l\u2019assist\u00e8ncia d\u2019Alba Verg\u00e9s, Consellera de Salut de la Generalitat de Catalunya, Ra\u00fcl Blanco, Secretari General d\u2019Ind\u00fastria i PYME en el Ministeri d\u2019Ind\u00fastria, Comer\u00e7 i Turisme, Albert Barber\u00e0, Director General de Recerca i Innovaci\u00f3 en Salut a la Generalitat de Catalunya i Joan Elias, rector de la Universitat de Barcelona, se celebrar\u00e0 el proper 27 de mar\u00e7 a Gav\u00e0, Barcelona. El principal objectiu \u00e9s impulsar projectes d\u2019investigaci\u00f3 per a la prevenci\u00f3 i el tractament de c\u00e0ncer a trav\u00e9s de l\u2019Oncobell, el programa d\u2019investigaci\u00f3 de l\u2019IDIBELL centrat en ter\u00e0pies experimentals i mecanismes moleculars en c\u00e0ncer.<\/p>\n<p>\u00a0<\/p>\n<p>Aix\u00ed mateix, les empreses i els mitjans de comunicaci\u00f3 que desitgin col\u00b7laborar, poden posar-se en contacte amb els responsables de la campanya per tel\u00e8fon (+34 93 260 72 82), per correu electr\u00f2nic (<a href=\"mailto:salvemvides@idibell.cat\">salvemvides@idibell.cat<\/a>) o a trav\u00e9s del formulari disponible a la web de la campanya: <a href=\"http:\/\/www.josalvovides.cat\">www.josalvovides.cat<\/a>.<\/p>\n<p>\u00a0<\/p>\n<p><strong>Patrocinen la campanya:<\/strong><br \/>Ad Salutem, Astra Zeneca, Bristol Myers Squibb, Boehringer Ingelheim, Catorze, Caves Torell\u00f3, Corporaci\u00f3 Catalana de Mitjans Audiovisuals, FGC-Ferrocarrils de la Generalitat de Catalunya, Gin Nut,Jubany, Naci\u00f3 digital, Renfe, TMB-Transport Metropolitans de Barcelona y TRAM.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s referent en el tractament de tumors minoritaris i ter\u00e0pies personalitzades.<\/p>\n","protected":false},"author":6,"featured_media":10504,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332],"tags":[],"class_list":["post-7503","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 18:19:43","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7503","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=7503"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/7503\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/10504"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=7503"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=7503"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=7503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}